Genome-wide differentially expressed gene analyses identified multiple genes representing pre-existing antitumor immunity as the top features associated with tumor response, including those immune cell-related genes (PTPRC, CD3E, CD8A, MS4A1, and IGHG4); cytotoxic T cell signature (IFNG, GZMH, GZMK, KLRD1, and IRF1); chemokines (CXCL13, CXCL9, CCL17, and CCL22), and immune checkpoint target genes (CD274, CTLA4, LAG3, and TIGIT, Figure 4A). This evidence concerns the gene PTPRC and neoplasm.